Michael Distler of D.S. Biomedical L.L.C. describes key products including the Delta Scanner and StimLink software, an electronic biofeedback nerve stimulator and data collection software. The core market is therapy and pain management. Competition is limited as this late stage device can perform analysis and customized treatment. With FDA clearance and clinical trials, the global market potential exceeds $500 million due to treatment of various unproven ailments with promising results such as partial paralysis reversal. Upon regulatory approval and intellectual property protection, the company will pursue acquisition by a large manufacturer to mass produce and market the products globally.